ATYR - aTyr Pharma, Inc.

ATYR - aTyr Pharma, Inc.

https://atyrpharma.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

New Mountain Finance, Texas Instruments, Analog Devices And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Akso Health ( NASDAQ:AHG ) , Analog Devices ( NASDAQ:ADI )

Benzinga • 3 hours, 38 minutes ago • score: -0.07

U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Monday. Shares of New Mountain Finance Corporation NMFC fell sharply in pre-market trading. B of A Securities analyst Derek Hewett downgraded New Mountain Finance from Buy to Underperform and cut the ...

1 Small-Cap Biotech Stock Poised for a Breakout

Motley Fool • 4 days, 1 hour ago • score: 0.30

The next couple of weeks could reveal a great deal about this stock's prospects.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 week, 2 days ago • score: 0.38

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule ...

Behind the Scenes of aTyr Pharma's Latest Options Trends - aTyr Pharma ( NASDAQ:ATYR )

Benzinga • 1 week, 3 days ago • score: 0.24

Investors with a lot of money to spend have taken a bullish stance on aTyr Pharma ATYR. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.

52W High

$7.29

52W Low

$1.67

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.01

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.81

EV/Revenue (<3 favorable)

132.17

P/S (TTM) (<3 favorable)

1147.59

P/B (<3 favorable)

7.34

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

2.03%

Institutions (25–75% balanced)

68.64%

Shares Outstanding

97,987,000

Float

95,966,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-54,233,000

EPS (TTM)

-0.79

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.85%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0487

Previous

0.0660

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025